## Jack D Bui

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6857050/publications.pdf

Version: 2024-02-01

|          |                | 186265       | 182427         |
|----------|----------------|--------------|----------------|
| 52       | 4,147          | 28           | 51             |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
| 53       | 53             | 53           | 7252           |
| 33       | 33             | 33           | 1232           |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| #  | Article  | IF          | CITATIONS |
|----|--|-------------|-----------|
| 1  | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.   | 28.9        | 691       |
| 2  | A critical function for type I interferons in cancer immunoediting. Nature Immunology, 2005, 6, 722-729.   | 14.5        | 516       |
| 3  | Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Journal of Experimental Medicine, 2012, 209, 1869-1882.  | 8.5         | 281       |
| 4  | Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Current Opinion in Immunology, 2007, 19, 203-208.   | <b>5.</b> 5 | 270       |
| 5  | PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity, 2019, 51, 1059-1073.e9.   | 14.3        | 229       |
| 6  | Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14211-14216.  | 7.1         | 186       |
| 7  | Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 852-854. | 0.8         | 145       |
| 8  | Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nature Communications, 2021, 12, 1999.  | 12.8        | 140       |
| 9  | Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Science Immunology, 2020, 5, .   | 11.9        | 127       |
| 10 | Interferon- $\hat{I}^3$ and Cancer Immunoediting. Immunologic Research, 2005, 32, 231-246.   | 2.9         | 123       |
| 11 | Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. Cell Reports, 2016, 16, 2348-2358.  | 6.4         | 107       |
| 12 | Cutting Edge: Down-Regulation of MHC Class I-Related Chain A on Tumor Cells by IFN-Î <sup>3</sup> -Induced MicroRNA. Journal of Immunology, 2009, 182, 39-43.  | 0.8         | 100       |
| 13 | Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins. Cancer Research, 2006, 66, 7301-7309.   | 0.9         | 98        |
| 14 | IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors. Journal of Immunology, 2006, 176, 905-913.  | 0.8         | 94        |
| 15 | Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells. Cell Reports, 2014, 7, 989-998.  | 6.4         | 73        |
| 16 | Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody. Transplantation, 2008, 86, 137-147.   | 1.0         | 70        |
| 17 | The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth. Journal of Immunology, 2010, 184, 369-378.   | 0.8         | 64        |
| 18 | Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. Cancer Research, 2019, 79, 1996-2008.   | 0.9         | 62        |

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Increased Foxp3 + Helios + Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biology of Blood and Marrow Transplantation, 2017, 23, 625-634. | 2.0  | 59        |
| 20 | elF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. Cancer Research, 2017, 77, 1997-2007.   | 0.9  | 57        |
| 21 | Integrin Activation Controls Regulatory T Cell–Mediated Peripheral Tolerance. Journal of Immunology, 2018, 200, 4012-4023.   | 0.8  | 44        |
| 22 | Survival of syngeneic and allogeneic iPSC–derived neural precursors after spinal grafting in minipigs. Science Translational Medicine, 2018, 10, .   | 12.4 | 42        |
| 23 | Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nature Biomedical Engineering, 2022, 6, 882-897.   | 22.5 | 41        |
| 24 | Siglec-7 engagement by GBS $\hat{l}^2$ -protein suppresses pyroptotic cell death of natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10410-10415.   | 7.1  | 38        |
| 25 | Cell-cell fusion as a mechanism of DNA exchange in cancer. Oncotarget, 2018, 9, 6156-6173.   | 1.8  | 37        |
| 26 | Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. Journal of Clinical Investigation, 2017, 127, 3609-3623.  | 8.2  | 35        |
| 27 | Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. Nature Cell Biology, 2022, 24, 954-967.   | 10.3 | 35        |
| 28 | Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Haploinsufficiency. Journal of Immunology, 2015, 194, 2551-2560.   | 0.8  | 32        |
| 29 | Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition. Oncotarget, 2016, 7, 21527-21541.  | 1.8  | 32        |
| 30 | Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection. Scientific Reports, 2018, 8, 13670.   | 3.3  | 29        |
| 31 | Elongated neutrophil-derived structures are blood-borne microparticles formed by rolling neutrophils during sepsis. Journal of Experimental Medicine, 2021, 218, .   | 8.5  | 29        |
| 32 | Cancer Immunoediting of the NK Group 2D Ligand H60a. Journal of Immunology, 2011, 187, 3538-3545.  | 0.8  | 26        |
| 33 | Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunology Research, 2016, 4, 799-811.  | 3.4  | 25        |
| 34 | Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: Effect on spinally grafted human neural precursor survival. Experimental Neurology, 2013, 248, 85-99.   | 4.1  | 24        |
| 35 | Mechanisms regulating immune surveillance of cellular stress in cancer. Cellular and Molecular Life Sciences, 2018, 75, 225-240.   | 5.4  | 22        |
| 36 | The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance. Cytokine, 2017, 91, 10-12.   | 3.2  | 19        |

| #  | Article   | IF  | Citations |
|----|---|-----|-----------|
| 37 | Tumor-expressed IL-17D recruits NK cells to reject tumors. Oncolmmunology, 2014, 3, e954853.  |     | 18        |
| 38 | Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3′UTR as a regulator of H60a expression. Molecular Immunology, 2011, 48, 539-545.                                       | 2.2 | 16        |
| 39 | Hormesis in cancer immunology. Oncolmmunology, 2014, 3, e29312.   | 4.6 | 16        |
| 40 | Drak2 is not required for tumor surveillance and suppression. International Immunology, 2015, 27, 161-166.  | 4.0 | 13        |
| 41 | Morphometric analysis of immunoselection against hyperploid cancer cells. Oncotarget, 2015, 6, 41204-41215.   | 1.8 | 13        |
| 42 | Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. Oncolmmunology, 2017, 6, e1268310.   | 4.6 | 11        |
| 43 | The Next Frontier: Head and Neck Cancer Immunoprevention. Cancer Prevention Research, 2017, 10, 681-683.  | 1.5 | 9         |
| 44 | Innate sensing of cancer's non-immunologic hallmarks. Current Opinion in Immunology, 2018, 50, 1-8.   | 5.5 | 9         |
| 45 | Machine Learning of Discriminative Gate Locations for Clinical Diagnosis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 296-307.                        | 1.5 | 8         |
| 46 | AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. Clinical Cancer Research, 2022, 28, 2646-2656.  | 7.0 | 8         |
| 47 | Automated Analysis of Clinical Flow Cytometry Data. Clinics in Laboratory Medicine, 2017, 37, 931-944.  | 1.4 | 7         |
| 48 | The nuclear factorâ€ĤB pathway downâ€regulates expression of the NKG 2D ligand H60a in vitro : implications for use of nuclear factorâ€ĤB inhibitors in cancer therapy. Immunology, 2013, 139, 265-274. | 4.4 | 6         |
| 49 | Evaluation of IL-17D in Host Immunity to Group A <i>Streptococcus</i> Infection. Journal of Immunology, 2020, 205, 3122-3129.   | 0.8 | 5         |
| 50 | Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.<br>Oncolmmunology, 2019, 8, e1404212.   | 4.6 | 4         |
| 51 | Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology, 2011, 133, 197-205.   | 4.4 | 2         |
| 52 | Neutrophils form elongated shearâ€derived particles (SDP) via shedding tethers and slings. FASEB Journal, 2018, 32, 574.6.  | 0.5 | 0         |